Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Allez

Showing results (171-180 of 205) with videos related to

Pageof 21
Sort By:
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2021
Determinants of IBD-related disability: a cross-sectional survey from the GETAIDJenny Tannoury, Maria Nachury, Carole Martins, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA StudyGeert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Journal of Crohn'S & Colitis|September 8, 2025
Blood proteomic signatures associated with disease activity in inflammatory bowel diseasesMaëva Veyssière, Nassim Hammoudi, Lionel Le Bourhis, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 28, 2023
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAIDRose Al Bacha, Yoram Bouhnik, Melanie Serrero, et al.
Gastroenterology|January 11, 2018
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's DiseaseGeert D'Haens, Severine Vermeire, Guy Lambrecht, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2022
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAIDAurelien Amiot, Philippe Seksik, Jean-Marie Reimund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|July 13, 2016
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID CohortYael Abitbol, David Laharie, Jacques Cosnes, et al.
Pageof 21

Showing results (171-180 of 205) with videos related to

Sort By:
Pageof 21
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2021
Determinants of IBD-related disability: a cross-sectional survey from the GETAIDJenny Tannoury, Maria Nachury, Carole Martins, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA StudyGeert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Journal of Crohn'S & Colitis|September 8, 2025
Blood proteomic signatures associated with disease activity in inflammatory bowel diseasesMaëva Veyssière, Nassim Hammoudi, Lionel Le Bourhis, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 28, 2023
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAIDRose Al Bacha, Yoram Bouhnik, Melanie Serrero, et al.
Gastroenterology|January 11, 2018
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's DiseaseGeert D'Haens, Severine Vermeire, Guy Lambrecht, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2022
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAIDAurelien Amiot, Philippe Seksik, Jean-Marie Reimund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|July 13, 2016
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID CohortYael Abitbol, David Laharie, Jacques Cosnes, et al.
Pageof 21